Q1 Earnings Forecast for Nuvalent Issued By HC Wainwright

Nuvalent, Inc. (NASDAQ:NUVL) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Nuvalent in a note issued to investors on Monday, May 11th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($1.07) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $155.00 price target on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($5.79) per share. HC Wainwright also issued estimates for Nuvalent’s FY2030 earnings at $2.33 EPS.

Other equities research analysts also recently issued research reports about the company. Wedbush reiterated an “outperform” rating and issued a $125.00 price objective on shares of Nuvalent in a report on Wednesday, April 8th. Wells Fargo & Company began coverage on Nuvalent in a research note on Monday, March 30th. They set an “overweight” rating and a $116.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Finally, Cantor Fitzgerald upped their price target on Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $137.25.

Nuvalent Trading Down 0.7%

NUVL stock opened at $104.55 on Tuesday. The company has a market capitalization of $8.22 billion, a PE ratio of -17.25 and a beta of 1.15. Nuvalent has a 12-month low of $68.64 and a 12-month high of $113.01. The business’s fifty day moving average price is $101.97 and its 200 day moving average price is $102.45.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the previous year, the firm posted ($1.18) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NUVL. RA Capital Management L.P. acquired a new position in shares of Nuvalent during the 3rd quarter worth about $107,794,000. Wellington Management Group LLP boosted its position in shares of Nuvalent by 46.0% during the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock worth $198,979,000 after acquiring an additional 724,491 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Nuvalent by 13.9% during the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock worth $527,521,000 after acquiring an additional 639,264 shares in the last quarter. Norges Bank acquired a new position in shares of Nuvalent during the 4th quarter worth about $57,763,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Nuvalent by 32.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock worth $221,826,000 after acquiring an additional 545,542 shares in the last quarter. 97.26% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Nuvalent news, CFO Alexandra Balcom sold 11,430 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $105.21, for a total transaction of $1,202,550.30. Following the sale, the chief financial officer owned 85,533 shares in the company, valued at $8,998,926.93. This represents a 11.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $104.48, for a total value of $323,156.64. Following the sale, the insider owned 65,604 shares in the company, valued at approximately $6,854,305.92. This trade represents a 4.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 80,023 shares of company stock worth $8,235,217 in the last quarter. Company insiders own 10.20% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.